Naia Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Naia Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014135
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Naia Ltd (Naia) is a funding and developing company that address regional and global medical needs. The company develops and manufactures therapeutics for metabolic and rare diseases. It provides global drug development through funding, clinical development, organizational structure and regulatory approval. Naia’s pipeline products include NC 101 a Glucagon-like peptide-1 (GLP-1)receptor agonists for the treatment of Type 2 diabetes and non-alcoholic steatohepatitis (NASH); NB1001 for the treatment of Type 2 diabetes and short bowel syndrome; and NB1002 for rare diseases. The company operates through pharma companies and contract research organizations. It operates in Hong Kong, Ireland, Singapore, the UK and the US. Naia is headquartered in Richmond, California, the US.

Naia Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Naia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Naia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Naia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Naia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Naia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Naia Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Naia Rare Diseases to Raise Funds through Series B Financing 10
Naia Raises USD5.3 Million in Series A Financing 11
Partnerships 12
Naia Enters into Agreement with Pharco Pharma 12
Licensing Agreements 13
Amunix Enters into Licensing Agreement with Naia for GLP-1-XTEN 13
Amunix Enters into Licensing Agreement with Naia for GLP-2-XTEN 14
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 15
Naia Ltd – Key Competitors 16
Naia Ltd – Key Employees 17
Naia Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Jan 07, 2016: Naia Rare Diseases a subsidiary of Naia Limited, Forms Scientific Advisory Board Comprised of Internationally Renowned Experts and Scientists 19
Product Approvals 20
Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases 20
Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Naia Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Naia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Naia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Naia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Naia Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Naia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Naia Rare Diseases to Raise Funds through Series B Financing 10
Naia Raises USD5.3 Million in Series A Financing 11
Naia Enters into Agreement with Pharco Pharma 12
Amunix Enters into Licensing Agreement with Naia for GLP-1-XTEN 13
Amunix Enters into Licensing Agreement with Naia for GLP-2-XTEN 14
Naia Enters into Licensing Agreement with Cedars-Sinai Medical Center 15
Naia Ltd, Key Competitors 16
Naia Ltd, Key Employees 17
Naia Ltd, Subsidiaries 18

★海外企業調査レポート[Naia Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Protalex Inc (PRTX)-製薬・医療分野:企業M&A・提携分析
    Summary Protalex Inc (Protalex) is a biopharmaceutical company that develops and offers drugs for autoimmune and inflammatory diseases. The company’s product includes PRTX-100, a formulation of staphylococcal protein A, which is an immune modulating protein produced by Staphylococcus aureus bacteria …
  • Zhejiang Huahai Pharmaceutical Co Ltd (600521):企業の財務・戦略的SWOT分析
    Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • SRS Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary SRS Medical Systems Inc (SRS Medical) is a medical device company that designs, manufactures and markets diagnostics and disposable products. The company offers spanner, urocuff test systems, urodynamic systems, uroflows, uroscan bladder ultrasound systems and disposables. Its disposables co …
  • CCP Technologies Ltd (AGX)-製薬・医療分野:企業M&A・提携分析
    Summary CCP Technologies Ltd (CCP), formerly Agenix Ltd is a biotechnology company that offers molecule drugs. The company develops small molecule drugs and monoclonal antibody-based diagnostics for the treatment of various diseases. It develops DiagnostIQ rapid point-of-care human diagnostic techno …
  • Mitsubishi Chemical Corp:企業の戦略的SWOT分析
    Mitsubishi Chemical Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Omron Corp (6645):企業の財務・戦略的SWOT分析
    Omron Corp (6645) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Valeo SA (FR):企業の財務・戦略的SWOT分析
    Valeo SA (FR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Lexicon Pharmaceuticals Inc (LXRX):企業の財務・戦略的SWOT分析
    Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • NV Bekaert SA:企業の戦略・SWOT・財務情報
    NV Bekaert SA - Strategy, SWOT and Corporate Finance Report Summary NV Bekaert SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ardent Health Services:企業の戦略・SWOT・財務分析
    Ardent Health Services - Strategy, SWOT and Corporate Finance Report Summary Ardent Health Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Suncor Energy Inc (SU):石油・ガス:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • SCC Soft Computer:企業の戦略的SWOT分析
    SCC Soft Computer - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Rapid Pathogen Screening Inc:医療機器:M&Aディール及び事業提携情報
    Summary Rapid Pathogen Screening Inc (RPS) is a biotechnology company that designs, develops, manufactures and markets point-of-care diagnostic tests. The company uses its patented direct sampling micro-filtration and direct multi-planar chromafiltography (DMC) technology to develop various tests. I …
  • Nelnet, Inc.:企業の戦略・SWOT・財務情報
    Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dana Petroleum Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Dana Petroleum Ltd (Dana), a wholly-owned subsidiary of Korea National Oil Corp (KNOC), is an upstream oil and gas company. It explores, develops and produces oil and gas from its assets in the Europe and the Middle East. The company has interests and operations in the UK, the Netherlands, D …
  • Okinawa Electric Power Company Incorporated (9511):企業の財務・戦略的SWOT分析
    Okinawa Electric Power Company Incorporated (9511) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Avaya Inc:企業の戦略的SWOT分析
    Avaya Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • WPX Energy Inc (WPX):企業の財務・戦略的SWOT分析
    WPX Energy Inc (WPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ameren Corporation:企業の戦略・SWOT・財務情報
    Ameren Corporation - Strategy, SWOT and Corporate Finance Report Summary Ameren Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Deloitte Touche Tohmatsu Ltd:企業の戦略的SWOT分析
    Deloitte Touche Tohmatsu Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆